Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, Barclays Analyst Says

Bausch + Lomb logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays raised its Bausch + Lomb price target from $24 to $27 and maintained an “overweight” rating, implying 28.57% upside from the prior close.
  • Analyst views are mixed: the consensus rating is “Hold,” with a consensus price target of $21.08.
  • Bausch + Lomb reported quarterly EPS of $0.34, beating the $0.21 estimate, while revenue rose 7.3% year over year to $1.38 billion.
  • MarketBeat previews the top five stocks to own by December 1st.

Bausch + Lomb (NYSE:BLCO - Get Free Report) had its price target hoisted by investment analysts at Barclays from $24.00 to $27.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's price target points to a potential upside of 28.57% from the company's previous close.

Several other brokerages also recently weighed in on BLCO. Citigroup raised their price target on Bausch + Lomb from $21.00 to $23.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. Leerink Partners began coverage on shares of Bausch + Lomb in a report on Wednesday, September 9th. They set an "outperform" rating and a $24.00 price objective on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Bausch + Lomb in a report on Tuesday, September 15th. UBS Group began coverage on shares of Bausch + Lomb in a research note on Thursday, July 30th. They set a "buy" rating and a $21.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Bausch + Lomb from $16.00 to $22.00 and gave the company a "neutral" rating in a report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $21.08.

Check Out Our Latest Research Report on Bausch + Lomb

Bausch + Lomb Stock Performance

Shares of BLCO opened at $21.00 on Tuesday. Bausch + Lomb has a 12 month low of $14.44 and a 12 month high of $21.40. The stock has a fifty day moving average price of $18.04 and a 200-day moving average price of $16.88. The company has a current ratio of 1.56, a quick ratio of 1.04 and a debt-to-equity ratio of 0.78. The firm has a market cap of $7.52 billion, a PE ratio of -67.53, a P/E/G ratio of 0.56 and a beta of 0.52.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.13. Bausch + Lomb had a positive return on equity of 5.01% and a negative net margin of 2.05%. The firm had revenue of $1.38 billion for the quarter, compared to the consensus estimate of $1.37 billion. During the same period in the previous year, the business earned $0.18 EPS. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. Equities research analysts predict that Bausch + Lomb will post 0.94 earnings per share for the current fiscal year.

Insider Transactions at Bausch + Lomb

In other Bausch + Lomb news, CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $20.48, for a total transaction of $2,294,067.20. Following the completion of the sale, the chief accounting officer directly owned 45,831 shares in the company, valued at approximately $938,618.88. The trade was a 70.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.45% of the company's stock.

Institutional Trading of Bausch + Lomb

A number of hedge funds and other institutional investors have recently made changes to their positions in BLCO. Roxbury Financial LLC acquired a new position in Bausch + Lomb during the third quarter valued at $33,000. Royal Bank of Canada raised its stake in shares of Bausch + Lomb by 67.1% during the 1st quarter. Royal Bank of Canada now owns 3,657 shares of the company's stock valued at $58,000 after buying an additional 1,468 shares during the last quarter. State of Wyoming lifted its holdings in shares of Bausch + Lomb by 6.9% in the 3rd quarter. State of Wyoming now owns 13,772 shares of the company's stock valued at $234,000 after buying an additional 887 shares during the period. R Squared Ltd lifted its holdings in shares of Bausch + Lomb by 46.0% in the 3rd quarter. R Squared Ltd now owns 17,452 shares of the company's stock valued at $297,000 after buying an additional 5,502 shares during the period. Finally, Handelsbanken Fonder AB lifted its holdings in shares of Bausch + Lomb by 5.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company's stock valued at $364,000 after buying an additional 1,100 shares during the period. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Company Profile

(Get Free Report)

Bausch + Lomb Corporation is an eye-health company that develops, manufactures and markets products for consumers, eye-care professionals and surgical teams. Its business spans vision care, pharmaceuticals and surgical devices. Its products include contact lenses and lens-care solutions, as well as eye-health medicines and nutritional supplements. The company also supplies equipment, technologies and related products used in eye surgery and other ophthalmic procedures. Founded in Rochester, New York, in 1853 by John Jacob Bausch and Henry Lomb, the company serves customers in more than 100 countries.

Further Reading

Analyst Recommendations for Bausch + Lomb (NYSE:BLCO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bausch + Lomb Right Now?

Before you consider Bausch + Lomb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.

While Bausch + Lomb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines